Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 4.5% – What’s Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) rose 4.5% during trading on Monday . The company traded as high as $6.68 and last traded at $6.64. Approximately 6,581,735 shares were traded during trading, a decline of 36% from the average daily volume of 10,331,976 shares. The stock had previously closed at $6.35.

Analyst Ratings Changes

RXRX has been the topic of a number of research analyst reports. KeyCorp dropped their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Leerink Partners dropped their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research report on Friday, February 28th. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. Finally, Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Recursion Pharmaceuticals has an average rating of “Hold” and an average target price of $8.25.

Recursion Pharmaceuticals Stock Performance

The stock has a 50-day moving average of $7.54 and a 200-day moving average of $7.02. The firm has a market cap of $2.74 billion, a price-to-earnings ratio of -4.44 and a beta of 0.85. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. During the same period in the prior year, the business posted ($0.42) EPS. The firm’s quarterly revenue was down 57.8% compared to the same quarter last year. As a group, analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Decker Retirement Planning Inc. bought a new position in Recursion Pharmaceuticals in the fourth quarter valued at approximately $26,000. Private Trust Co. NA bought a new position in Recursion Pharmaceuticals in the fourth quarter valued at approximately $27,000. GAMMA Investing LLC grew its stake in Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock valued at $35,000 after purchasing an additional 4,948 shares in the last quarter. KBC Group NV grew its stake in Recursion Pharmaceuticals by 79.9% in the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after purchasing an additional 3,377 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its stake in Recursion Pharmaceuticals by 21.1% in the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock valued at $52,000 after purchasing an additional 1,353 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.